US group Barr Pharmaceuticals says that strong sales of generic products and good performances of new alliances with Israel’s Teva Pharmaceutical [[08/09/05e]] and Kos Pharmaceuticals [[14/04/05e]] helped drive a 27% leap in revenues to $310 million dollars for its fiscal first quarter.

This propelled net income 60% to $83.2 million, or $0.78 per share, beating the consensus estimate of analysts surveyed by Thomson First Call by $0.01.

The group’s solid performance during the quarter enabled the firm to reiterate its full-year (ended June 30) earnings per share target of $2.95-$3.10; falling in line with analysts’ general expectations of $3.08 a share.